RxDoctor Payments Data

Makenzie Record, APRN

Family · Harrodsburg, KYNPI 1255060554

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 66 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$354
  • GSK$215
  • Novo Nordisk$153
  • Lilly USA, LLC$72
  • Almatica Pharma LLC$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
  • plus $187 from 9 others

What the payments were for

  • Food & beverage$1,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,085 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$37,660
Medicare patients
237
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$83,285
JanuviaSitagliptin Phosphate54$71,706
EliquisApixaban56$55,487
TrulicityDulaglutide32$51,526
MounjaroTirzepatide36$48,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$44,400
JardianceEmpagliflozin32$44,385
FarxigaDapagliflozin Propanediol35$37,027
XareltoRivaroxaban17$14,902
Tresiba Flextouch U-200Insulin Degludec11$12,726
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$11,763
LyricaPregabalin12$10,710
Breo ElliptaFluticasone/Vilanterol14$10,622
VeozahFezolinetant12$6,208
SymbicortBudesonide/Formoterol Fumarate16$5,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$72$100,32168 claims
Novo NordiskOzempic$153$83,28568 claims
MerckJanuvia$30$71,70654 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$215$66,78594 claims
Boehringer IngelheimJardiance$14$44,38532 claims
AstraZenecaFarxiga, Symbicort$15$42,43351 claims
Astellas Pharma US IncVeozah$20$6,20812 claims
AbbVieSynthroid$354$1,54418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Harrodsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →